| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
13,320,000 |
| Market
Cap: |
138.26(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$10.38 - $10.38 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile enVVeno Medical is a med-tech company focused on improving the standard of care in the treatment of venous disease. Co. is developing tissue-based solutions that are designed to be life sustaining or life enhancing for patients with Chronic Venous Insufficiency (CVI). CVI occurs when valves inside of the veins of the leg fail, resulting in insufficient blood being returned to the heart. Co.'s primary product is a porcine based device to be surgically implanted in the deep venous system of the leg and is called the VenoValve®. In addition to the VenoValve, Co. has a second product in the early stages of development called enVVe.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
11,251 |
| Total Buy Value |
$0 |
$0 |
$0 |
$60,941 |
| Total People Bought |
0 |
0 |
0 |
3 |
| Total Buy Transactions |
0 |
0 |
0 |
3 |
| Total Shares Sold |
8,334 |
8,334 |
8,334 |
8,334 |
| Total Sell Value |
$51,837 |
$51,837 |
$51,837 |
$51,837 |
| Total People Sold |
1 |
1 |
1 |
1 |
| Total Sell Transactions |
1 |
1 |
1 |
1 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Biodyne Holding, S.a. |
10% Owner |
– – • |
2019-05-21 |
4 |
D |
$0.00 |
$0 |
D/D |
(177,740) |
4,265,829 |
|
- |
|
| Berman Robert Andrew |
Chief Executive Officer |
• • – |
2019-03-12 |
4/A |
B |
$1.36 |
$25,000 |
D/D |
18,382 |
18,382 |
2.81 |
- |
|
| Berman Robert Andrew |
Chief Executive Officer |
• • – |
2019-03-12 |
4 |
B |
$1.15 |
$25,001 |
D/D |
21,740 |
21,740 |
2.81 |
- |
|
| Duhay Francis |
Director |
– • – |
2018-11-27 |
4 |
A |
$2.57 |
$75,000 |
D/D |
29,183 |
29,183 |
|
- |
|
| Shrivastava Sanjay |
Director |
– • – |
2018-11-27 |
4 |
A |
$2.57 |
$75,000 |
D/D |
29,183 |
29,183 |
|
- |
|
| Robins Marcus W. |
Director |
– • – |
2018-11-27 |
4 |
A |
$2.57 |
$75,000 |
D/D |
29,183 |
29,183 |
|
- |
|
| Broennimann Benedict |
Chief Medical Officer, OUS |
• – – |
2018-11-27 |
4 |
A |
$0.00 |
$0 |
I/I |
3,334 |
437,778 |
|
- |
|
57 Records found
|
|
Page 3 of 3 |
|
|
